Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Evaluate the feasibility of adjuvant comprehensive radiation therapy via IMRT with daily set-up position verified using 3D verification
研究概览
简要总结
This study delivers radiation therapy to any residual breast tissue and the chest wall plus lymph node areas around the breast. These lymph node areas are under the arm, around the collar bone, and under the sternum (breastbone).
详细描述
IMRT treatment uses a computer-controlled x-ray (CT) to deliver radiation beams at several different angles and strengths to deliver precise doses to the regions at risk for recurrence of breast cancer while reducing or sparing the dose to critical structures (heart, lungs) and nearby normal tissue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female gender
- •Age ≥ 18 years
- •Invasive primary female breast cancer
- •Pathologically proven regional nodal metastasis
- •Status post mastectomy or partial mastectomy with an assessment of axillary nodes via sentinel lymph node biopsy and/or axillary lymph node dissection.
- •Signed study specific consent form
排除标准
- •Distant metastasis
- •Currently Pregnant
- •Psychiatric or addictive disorders that preclude informed consent
- •Time from initial diagnosis to the start of radiation therapy > one year
- •Estimated life expectancy judged to be < one year
- •Prior radiation to the ipsilateral breast or chest wall
- •Primary breast cancer is lymphoma or sarcoma
- •Patients being treated with concurrent chemotherapy.
研究组 & 干预措施
IMRT
The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
干预措施: IMRT (Radiation)
结局指标
主要结局
Evaluate the feasibility of adjuvant comprehensive radiation therapy via IMRT with daily set-up position verified using 3D verification
时间窗: Within 1 year of protocol registration
The study will be deemed infeasible if greater than 10% of enrolled patients have at least one of the following outcomes: 1. Patient cannot be given the treatment because her anatomy is such that a dosimetrically satisfactory treatment plan cannot be devised for her. 2. Within 1 year of protocol registration, the patient develops radiation pneumonitis toxicity of greater than or equal to grade 3 by CTCAE scales. 3. Within 1 year of protocol registration, the patient develops any local or regional breast cancer recurrence. 4. Within 1 year of protocol registration, the patient dies from causes judged to be related to her treatment.
次要结局
- Evaluate the rate of radiation pneumonitis(6-8 weeks following completion of treatment, 3-4 months following completion of treatment, 6-8 months following completion of treatment, and 12-14 months following completion of treatment)
- Evaluate ipsilateral upper quadrant function(Pretreatment and 3-4 months following completion of treatment)
- Evaluate patient quality of life(Pretreatment, 6-8 months following completion of treatment, and 12-14 months following completion of treatment)
- Evaluate the rate and severity of both acute and late cutaneous toxicity(6-8 months following completion of treatment and 12-14 months following completion of treatment)
- Evaluate local-regional control rates(12-14 months following completion of radiation therapy)
- Evaluate patient set-up reproducibility in breast cancer patients treated with IMRT using daily 3D position verification(12-14 months following completion of treatment)
- Evaluate the rate and severity of late subcutaneous fibrosis(6-8 months following completion of treatment and 12-14 months following completion of treatment)